| Literature DB >> 35096566 |
Liang Zhao1, Guangyu Bai1, Ying Ji2, Yue Peng1, Ruochuan Zang1, Shugeng Gao1.
Abstract
INTRODUCTION: Stage IA lung adenocarcinoma manifested as part-solid nodules (PSNs), has attracted immense attention owing to its unique characteristics and the definition of its invasiveness remains unclear. We sought to develop a nomogram for predicting the status of lymph nodes of this kind of nodules.Entities:
Keywords: adenocarcinoma; lung; lymph node metastasis; nomogram; part-solid nodules
Year: 2022 PMID: 35096566 PMCID: PMC8794794 DOI: 10.3389/fonc.2021.749643
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The flow diagram of the patient selection. PSN, part-solid nodule; AIS, adenocarcinoma in situ; MIA, microinvasive adenocarcinoma.
Clinical and pathological characteristics of patients.
| Characteristics | Median (range) or number (%) | ||
|---|---|---|---|
| Training cohort | Validation cohort | Total | |
| Age | 58 (53–63) | 61 (56–67) | 59 (53–64) |
| Gender | |||
| Female | 150 (69.8) | 101 (62.7) | 251 (66.8) |
| Male | 65 (30.2) | 60 (37.3) | 125 (33.2) |
| cStage | |||
| cT1N0 | 215 (100) | 161 (100) | 376 (100) |
| cT1N1-2 | 0 (0) | 0 (0) | 0 (0) |
| pStage | |||
| pT1N0 | 173 (80.5) | 119 (73.9) | 292 (77.7) |
| pT1N1-2 | 42 (19.5) | 42 (26.1) | 84 (22.3) |
| Differentiation | |||
| High | 67 (31.2) | 60 (37.3) | 127 (33.8) |
| Median | 105 (48.8) | 48 (29.8) | 153 (40.7) |
| Low | 43 (20) | 53 (32.9) | 96 (25.5) |
| Micropapillary/solid subtype | |||
| Absent | 156 (72.6) | 118 (73.3) | 274 (72.9) |
| Present | 59 (27.4) | 43 (26.7) | 102 (27.1) |
| MVI | |||
| Yes | 24 (11.2) | 15 (9.3) | 39 (10.4) |
| No | 191 (88.8) | 146 (90.7) | 337 (89.6) |
| Vis PI | |||
| Yes | 1 (0.4) | 3 (1.9) | 4 (1.1) |
| No | 214 (99.6) | 158 (98.1) | 372 (98.9) |
| Nerve invasion | |||
| Yes | 2 (0.9) | 1 (0.6) | 3 (0.8) |
| No | 213 (99.1) | 160 (99.4) | 373 (99.2) |
| Necrosis | |||
| Yes | 3 (1.4) | 2 (1.2) | 5 (1.3) |
| No | 212 (98.6) | 159 (98.8) | 371 (98.7) |
| Tumor size (cm) | 1.98 (1.53–2.48) | 1.80 (1.40–2.30) | 1.93 (1.50–2.40) |
| Consolidation component length (cm) | 0.86 (0.49–1.53) | 0.92 (0.61–1.32) | 0.87 (0.50–1.47) |
| CTR | |||
| <0.61 | 138 (64.2) | 112 (69.6) | 250 (66.5) |
| >0.61 | 77 (35.8) | 49 (30.4) | 126 (33.5) |
MVI, microscopic vessel invasion; VisPI, visceral pleural infiltration; CTR, consolidation tumor ratio.
The consistency of the presence of micropapillary/solid subtype between frozen sections and paraffin sections.
| Frozen sections | Paraffin sections | Total | |
|---|---|---|---|
| Positive | Negative | ||
| Positive | 80 | 7 | 87 |
| Negative | 22 | 267 | 289 |
| Total | 102 | 274 | 376 |
The consistency of MVI between frozen sections and paraffin sections.
| Frozen sections | Paraffin sections | Total | |
|---|---|---|---|
| Positive | Negative | ||
| Positive | 20 | 2 | 22 |
| Negative | 19 | 335 | 354 |
| Total | 39 | 337 | 376 |
MVI, microscopic vessel invasion.
Figure 2A representative receiver operating characteristic (ROC) curve displayed the classification performance of consolidation tumor ratio (CTR). The cutoff value is 0.61, which means PSNs are more prone to have positive lymph nodes when CTR >0.61. The area under curve (AUC) is 0.866; 95% confidence interval (CI) is shown in blue shade (0.799, 0.934).
Univariate and multivariate analyses of lymph node metastasis.
| Variables | Univariate analysis | Multivariate analysis (before AIC) | Multivariate analysis (after AIC) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR |
| 95% CI | OR |
| 95% CI | OR |
| 95% CI | |
| Age | 1.01 | 0.56 | 0.97, 1.06 | 1.07 | 0.05 | 1.00, 1.14 | |||
| Gender (reference: female) | 1.2 | 0.61 | 0.60, 2.42 | ||||||
| Histological differentiation (reference: high) | |||||||||
| Median | 2.03 | 0.24 | 0.63, 6.59 | 0.29 | 0.13 | 0.06,1.43 | |||
| Low | 32.63 | <0.01* | 9.88, 107.79 | 1.61 | 0.62 | 0.25, 10.51 | |||
| Micropapillary/solid subtype(reference: no) | 15.23 | <0.01* | 6.97, 33.28 | 1.84 | 0.39 | 0.46, 7.36 | 5.09 | <0.01* | 1.80, 14.40 |
| MVI (reference: no) | 33.2 | <0.01* | 10.48, 105.16 | 24.03 | <0.01* | 4.21, 137.26 | 22.29 | <0.01* | 4.04, 122.92 |
| Tumor size | 2.03 | <0.01* | 1.30, 3.16 | 0.70 | 0.65 | 0.15, 3.24 | |||
| Consolidation component length | 6.61 | <0.01* | 3.69, 11.84 | 2.91 | 0.25 | 0.47, 18.09 | 1.63 | 0.31 | 0.64, 4.15 |
| CTR(reference: <0.61) | 38.15 | <0.01* | 12.82, 113.55 | 7.88 | 0.47 | 1.03,60.12 | 12.49 | <0.01* | 2.63, 59.40 |
OR, odds ratio; MVI, microscopic vessel invasion; Vis PI, visceral pleura invasion. *P value < 0.05.
Figure 3Nomogram for the prediction of lymph node metastasis of patients with lung adenocarcinoma manifested as PSNs. To use the nomogram, find the position of each variable on the corresponding axis, draw a line to the points axis for the number of points, add the points from all of the variables, and draw a line from the total points axis to determine the probabilities of lymph node metastasis at the lower line of the nomogram.
Figure 4Calibration plot comparing predicted and actual probability of lymph node metastasis in (A) training cohort (n = 215) and (B) validation cohort (n = 161).